“Tailored TAVI”: the importance of the deployment mechanism

Abstract

A 78-year-old man with a past medical history of hypertension, pulmonary thromboembolism, atrial fibrillation, and prostate cancer presented with dyspnea. The patient was diagnosed with severe aortic stenosis (mean gradient, 49 mmHg; area of 0.7 cm2), and severe ventricular hypertrophy. Heart function was preserved. The heart team decided to perform transcatheter aortic valve implantation (TAVI). Computed tomography revealed the presence of a scarcely calcified annulus with greater calcium distribution at the level of leaflet commissures and a 73.5-mm perimeter (figure 1). Figure 1. We decided to implant a 23-mm self-expandable, supra-annular, fully recapturable, and nonrepositionable ALLEGRA valve (New-Valve-Technology, Switzerland). The valve was predilated using a 20-mm balloon but showed pop-up and distal migration towards the outflow tract despite pacing (figure 2A,B). The same complication occurred with a 27-mm ALLEGRA device. We then attempted to use a 29-mm CoreValve Evolut PRO+ valve (Medtronic, United States), because this device is fully repositionable, but the same complication recurred even with pacing (figure 2C,D). Figure 2. Due to severe aortic regurgitation after the failed implantations, the patient became unstable (video 1 of the supplementary data). Considering the calcium distribution, we used the repositionable but not recapturable ACCURATE neo2 L valve (Boston Scientific, United States), which is equipped with...